AB 2034 defines any color additive, food additive, or dietary ingredient that induces cancer in humans or animals as unsafe for use in human food and then creates a California-managed system for permitting and tracking other additives introduced after 1958. The bill requires submitters to provide the safety information found in specific FDA notice regulations, publishes those notices in a searchable public database, and gives the Department authority to license, reassess, and revoke approvals.
The law matters because it builds a state-level premarket regime that sits alongside federal mechanisms (GRAS, FDA notices, and tolerance regulations). For manufacturers, importers, and ingredient suppliers it creates concrete deadlines, public disclosure obligations, and a recurring reassessment schedule; for public-health advocates it creates a centralized, searchable record of safety submissions and departmental decisions.
At a Glance
What It Does
AB 2034 treats carcinogenic additives as per se unsafe, requires notice submissions that mirror 21 C.F.R. 170.225–170.255 for additives introduced after 1958, publishes those notices in a public database, and establishes a state licensing process with public objection and revocation authority. It also mandates periodic reassessments of substance classes and allows the department to charge user fees.
Who It Affects
Manufacturers, formulators, and importers who introduce food additives or dietary ingredients into California markets after January 1, 1958; suppliers of such ingredients; and the California Department of Public Health (which must build the database and run the licensing and reassessment program). Retail food sellers are largely insulated via a limited sell-through provision.
Why It Matters
The bill creates a formal California premarket pathway and public record that can trigger reformulation, additional testing, or labeling changes, and it allows state regulators to withdraw approvals independently of federal action—potentially accelerating statewide restrictions and shaping market access for ingredient producers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 2034 begins by setting a bright-line safety threshold: any color additive, food additive, or dietary ingredient that is found to induce cancer in humans or animals will be considered unsafe for human food. That creates an explicit statutory basis for denying use in California based solely on carcinogenic findings, without requiring additional administrative rulemaking.
The bill draws a distinction between substance uses that are grandfathered and those that require affirmative notice and licensing. Substances widely used in the U.S. before January 1, 1958, with conventional processing and no known hazards, remain allowable without new notice.
Additives introduced after that date must follow a California notice pathway unless they already fall under federal tolerance/regulation, have an FDA GRAS letter, are recognized in federal regulations as prior-sanctioned/GRAS, are covered by effective premarket food-contact notifications, or have current FDA acknowledgement as a new dietary ingredient.For post‑1958 uses that require a California notice, the bill requires submitters to provide the information listed in 21 C.F.R. 170.225–170.255 and directs the Department to publish a searchable public database by July 1, 2027. The Department must verify notices for completeness within 60 days, either publish complete notices or issue rejection letters detailing missing information, and may redact trade secrets except for data necessary to establish safety.
After publication, the Department will issue licenses for uses introduced before July 1, 2027; for uses introduced on or after that date the bill imposes a 45‑day public objection window and requires the Department to decide whether to issue a license within 15 days after that window closes.The bill equips the Department to use outside evidence, consult OEHHA and DTSC, charge user fees, and revoke licenses if safety concerns emerge. It also sets a recurring reassessment duty: by July 1, 2030, and at least every three years thereafter, the Department must reassess the safety of at least 10 substances or substance classes (including additives, color additives, prior‑sanctioned substances, and dietary ingredients), and it may require manufacturers to supply updated safety evaluations.
Two practical limits reduce immediate disruption: an explicit small-business exemption (businesses with 100 or fewer employees) and a retail sell‑through allowance that lets in‑state sellers move products acquired before July 1, 2027 until their printed sell-by/expiration date or July 1, 2030—whichever comes first.
The Five Things You Need to Know
The bill treats any additive shown to induce cancer in humans or animals as categorically unsafe for human food under California law.
Submitters must provide the safety information listed in 21 C.F.R. 170.225–170.255; the Department must verify completeness within 60 days and either publish the notice or issue a rejection letter.
The Department must make a searchable public database available by July 1, 2027, and must include submitted safety data, departmental responses, and any issued licenses (with allowable redactions for trade secrets that do not affect safety data).
For new uses introduced on or after July 1, 2027, the Department opens a 45‑day public objection period and then has 15 days after the objection period to decide whether to issue a license; it may revoke licenses later based on new information.
The Department must begin reassessing at least 10 substances or classes by July 1, 2030 and at least every three years thereafter; small businesses (≤100 employees) are exempt and retailers may sell-through pre‑July 1, 2027 inventory until product expiration or July 1, 2030.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Carcinogenicity-based unsafe standard
This section says a color additive, food additive, or dietary ingredient is unsafe if it is found to induce cancer when ingested by humans or animals, or if appropriate tests show it induces cancer. Practically, this creates a statutory trigger that can be applied without waiting for separate tolerance-setting or federal action and can be used as a basis to prohibit use in California food.
Permitted uses and grandfathering criteria
The provision lists seven conditions that allow a substance or use to be treated as acceptable: widely used in the U.S. before January 1, 1958 without known harms; introduced after 1958 but cleared by the new notice and licensing pathway; subject to federal tolerance/regulation (including zero tolerance); covered by an FDA GRAS letter; recognized in federal regs as prior‑sanctioned/GRAS; covered by an effective food-contact premarket notification; or acknowledged by FDA as a new dietary ingredient. This section is the gatekeeper that separates grandfathered uses from those requiring affirmative California action.
Notice content, public database, and implementation reporting
The bill requires the Department to publish a public database by July 1, 2027 and to accept notices that include the same information required by 21 C.F.R. 170.225–170.255. The Department has 60 days to check a notice for completeness and either publish it or issue a rejection letter. Submitters may mark trade secrets, but the Department must not redact data necessary to establish safety. The Department must report to the Legislature and Governor on progress, obstacles, costs, and a projected completion date for the database by July 1, 2028.
Licensing process, public objections, and consultations
This section sets the licensing mechanics: for uses introduced before July 1, 2027 the Department issues licenses after publication; for uses introduced on or after that date the Department allows a 45‑day public objection period and then has 15 days post‑objection to decide. The Department will only issue a license if no reasonable safety questions are raised and must publish a letter summarizing concerns if it declines. It may rely on evidence beyond the submitted notice and must consult OEHHA and DTSC. Licenses can be transferred with notice to the Department.
Safety assessment criteria, revocation, fees, and periodic reassessment
When assessing safety, the Department must consider a broad set of factors (including dietary exposure estimates, cumulative effects, hazard and dose‑response, Proposition 65 status, and application of protective safety factors). The Department can revoke licenses if new information raises concerns and may create user fees for notices and reassessments. It must systematically reassess at least 10 substances or classes by July 1, 2030 and at least every three years thereafter, and it can require manufacturers to produce updated safety evaluations as part of reassessments.
Small-business exemption and retail sell-through
The statute exempts small businesses—defined as independently owned firms with 100 or fewer employees—from the article. It also permits retail establishments and certain food vendors to sell products acquired in California before July 1, 2027 that would otherwise be prohibited, up to the product’s printed expiration or July 1, 2030. That carve-out reduces immediate market disruption for front‑line sellers while the Department builds its program.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- California consumers and public-health advocates — gain a searchable public record of safety submissions and departmental actions, increasing transparency about what additives are proposed and how safety is justified.
- State regulators and scientists (CDPH, OEHHA, DTSC) — receive formal authority, statutory criteria, and a centralized database that improve monitoring and allow the Department to act independently of federal timelines.
- Manufacturers and ingredient suppliers who comply early — obtain state licenses that clarify market access in California and, by meeting the notice standards, reduce the risk of surprise enforcement actions.
Who Bears the Cost
- Manufacturers, formulators, and importers of post‑1958 additives — face new compliance costs: compiling 21 C.F.R.‑level safety dossiers, paying potential user fees, and responding to objections and reassessments.
- Medium‑sized companies and ingredient suppliers above the 100‑employee threshold — lack the small‑business exemption and therefore shoulder testing, notice, and licensing burdens that exempted smaller competitors avoid.
- California Department of Public Health — must build and operate a searchable database, verify notices, manage objection and licensing timelines, consult external agencies, and carry out reassessments, creating significant resource and staffing demands that the bill attempts to offset with fees.
Key Issues
The Core Tension
The central tension is between precaution and transparency on one hand—giving California regulators and the public more information and the ability to block potentially harmful additives—and regulatory certainty and market continuity on the other: imposing a state‑level premarket and reassessment regime increases compliance costs, creates potential divergence from federal standards, and risks supply‑chain disruption without clear procedural safeguards or funding commitments.
AB 2034 creates overlapping state-level authority alongside federal regulatory regimes (FDA GRAS notices, food-contact notifications, and tolerance regulations). That overlap raises practical questions about preemption, duplicative review, and which determinations govern market access when federal and state findings diverge—especially where a substance has federal recognition but a different evidentiary record under California’s reassessment criteria.
The statute permits reliance on outside evidence and consultation with OEHHA and DTSC, but it does not specify adjudicative procedures, appeal rights, or enforcement penalties for noncompliance, leaving procedural due-process and enforcement design to future regulation.
The bill’s transparency push also creates tension between public access and legitimate trade-secret protection: submitters can designate information as confidential, but the Department must not redact data necessary to establish safety. Determining what the department deems necessary for safety (and thus not redactable) will be a recurring source of dispute.
Finally, the small-business exemption and retail sell‑through carve-out blunt immediate disruption but also create competitive distortions and carve multiple pathways into the California market—potentially encouraging strategic behavior around company size, acquisition timing, or distribution channels to avoid requirements.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.